Detail
| LncRNA Name | lncRNA-NUTF2P3-001 |
| Synonyms | NUTF2P3 |
| Region | GRCh38_9:77580245-77580628 Sequence |
| Ensembl | ENSG00000228248 |
| RefSeq | NA |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | pancreatic cancer |
| ICD-0-3 | C25 |
| Methods | microarray, qPCR, RNAi, Western blot, Luciferase reporter assay, MTT assay etc. |
| Sample | pancreatic cancer tissues, cell lines (PANC-1 and BXPC-3) |
| Expression Pattern | up-regulated |
| Function Description | lncRNA-NUTF2P3-001 is upregulated in pancreatic cancer cells under hypoxia and CoCl2 treatment, which is attributed to the binding of hypoxia-inducible factor-1a (HIF-1a) to hypoxia response elements (HREs) in the upstream of KRAS promoter. Data from pancreatic cancer patients show a positive correlation between lncRNA-NUTF2P3-001 and KRAS, which is associated with advanced tumor stage and worse prognosis. Hence, our data provide a new lncRNA-mediated regulatory mechanism for the tumor oncogene KRAS and implicate that lncRNA-NUTF2P3-001 and miR-3923 can be applied as novel predictors and therapeutic targets for pancreatic cancer. |
| Pubmed ID | 26755660 |
| Year | 2016 |
| Title | Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway. |
| External Links |
| Links for lncRNA-NUTF2P3-001 | GenBank HGNC lncrnadb Noncode |
| Links for pancreatic cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.